These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 29056540)
1. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540 [TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108 [TBL] [Abstract][Full Text] [Related]
3. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539 [TBL] [Abstract][Full Text] [Related]
5. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Wei W; Wu P; Li L; Zhang ZH Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702 [TBL] [Abstract][Full Text] [Related]
7. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type. Wu W; Chen X; Li N; Luo Q; Zou L Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247 [TBL] [Abstract][Full Text] [Related]
8. Dynamic evaluation of the prognostic value of Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA. Liang JH; Wang L; Peter Gale R; Wu W; Xia Y; Fan L; Li JY; Xu W Blood Cancer J; 2017 Sep; 7(9):e608. PubMed ID: 29016569 [No Abstract] [Full Text] [Related]
10. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825 [TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213 [TBL] [Abstract][Full Text] [Related]
13. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707 [TBL] [Abstract][Full Text] [Related]
14. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers. Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294 [TBL] [Abstract][Full Text] [Related]
16. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients. Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma. Feng D; Yan Z; Fu B; Bai S; Zhu L; Gale RP; Xia Z; Liang Y; Wang H Hematology; 2024 Dec; 29(1):2402102. PubMed ID: 39268981 [TBL] [Abstract][Full Text] [Related]
18. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807 [TBL] [Abstract][Full Text] [Related]
19. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study]. Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837 [No Abstract] [Full Text] [Related]
20. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]